Jeremy Bender Sells 70,051 Shares of Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Stock

Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) CEO Jeremy Bender sold 70,051 shares of Day One Biopharmaceuticals stock in a transaction on Wednesday, May 1st. The shares were sold at an average price of $17.88, for a total transaction of $1,252,511.88. Following the completion of the sale, the chief executive officer now directly owns 651,762 shares of the company’s stock, valued at $11,653,504.56. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

Jeremy Bender also recently made the following trade(s):

• On Friday, May 3rd, Jeremy Bender sold 9,154 shares of Day One Biopharmaceuticals stock. The shares were sold at an average price of $17.85, for a total transaction of $163,398.90.
• On Friday, February 16th, Jeremy Bender sold 7,615 shares of Day One Biopharmaceuticals stock. The shares were sold at an average price of $15.25, for a total transaction of $116,128.75.

Day One Biopharmaceuticals Stock Performance

Day One Biopharmaceuticals stock opened at $17.17 on Monday. Day One Biopharmaceuticals, Inc. has a fifty-two week low of $9.67 and a fifty-two week high of $18.07. The stock has a market cap of $1.50 billion, a PE ratio of -7.21 and a beta of -1.44. The firm’s 50-day simple moving average is $15.45 and its 200 day simple moving average is $14.07.

Day One Biopharmaceuticals (NASDAQ:DAWN) last released its quarterly earnings results on Monday, February 26th. The company reported ($0.64) earnings per share for the quarter, missing the consensus estimate of ($0.57) by ($0.07). As a group, analysts predict that Day One Biopharmaceuticals, Inc. will post -2.67 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of brokerages have recently issued reports on DAWN. Piper Sandler reiterated an “overweight” rating and set a $40.00 price objective on shares of Day One Biopharmaceuticals in a report on Tuesday, March 26th. Wedbush reiterated an “outperform” rating and set a $33.00 price objective on shares of Day One Biopharmaceuticals in a report on Wednesday, April 24th. Oppenheimer reiterated a “market perform” rating on shares of Day One Biopharmaceuticals in a report on Tuesday, February 27th. Needham & Company LLC lifted their price objective on shares of Day One Biopharmaceuticals from $30.00 to $33.00 and gave the company a “buy” rating in a report on Wednesday, April 24th. Finally, JPMorgan Chase & Co. lifted their price objective on shares of Day One Biopharmaceuticals from $32.00 to $36.00 and gave the company an “overweight” rating in a report on Monday, April 22nd. One investment analyst has rated the stock with a hold rating and six have issued a buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $39.33.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. China Universal Asset Management Co. Ltd. boosted its stake in Day One Biopharmaceuticals by 67.1% in the first quarter. China Universal Asset Management Co. Ltd. now owns 16,817 shares of the company’s stock valued at $278,000 after acquiring an additional 6,750 shares during the last quarter. Hennion & Walsh Asset Management Inc. boosted its stake in Day One Biopharmaceuticals by 2.5% in the first quarter. Hennion & Walsh Asset Management Inc. now owns 59,289 shares of the company’s stock valued at $979,000 after acquiring an additional 1,445 shares during the last quarter. Fisher Asset Management LLC boosted its stake in Day One Biopharmaceuticals by 89.0% in the fourth quarter. Fisher Asset Management LLC now owns 68,446 shares of the company’s stock valued at $999,000 after acquiring an additional 32,238 shares during the last quarter. Wellington Management Group LLP boosted its stake in Day One Biopharmaceuticals by 77.7% in the fourth quarter. Wellington Management Group LLP now owns 208,969 shares of the company’s stock valued at $3,051,000 after acquiring an additional 91,393 shares during the last quarter. Finally, Goldman Sachs Group Inc. boosted its stake in Day One Biopharmaceuticals by 28.7% in the fourth quarter. Goldman Sachs Group Inc. now owns 2,118,849 shares of the company’s stock valued at $30,935,000 after acquiring an additional 472,654 shares during the last quarter. 87.95% of the stock is currently owned by hedge funds and other institutional investors.

Day One Biopharmaceuticals Company Profile

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.